Status:

COMPLETED

Etanercept (Enbrel®) in Psoriasis - Pediatrics

Lead Sponsor:

Amgen

Conditions:

Psoriasis

Eligibility:

All Genders

4-17 years

Phase:

PHASE3

Brief Summary

This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.

Detailed Description

On enrollment, participants underwent randomization in a 1:1 ratio to receive placebo or etanercept during the initial double-blind period. Participants could enter an escape group and receive open-la...

Eligibility Criteria

Inclusion

  • Patients with plaque psoriasis
  • Patient may not receive certain psoriasis medications during the study

Exclusion

    Key Trial Info

    Start Date :

    September 8 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2007

    Estimated Enrollment :

    211 Patients enrolled

    Trial Details

    Trial ID

    NCT00078819

    Start Date

    September 8 2004

    End Date

    June 1 2007

    Last Update

    July 29 2019

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.